CalAmp is a telematics solutions provider. The company's software applications, cloud services, and intelligent devices collect and assess data including industrial machines, commercial and passenger vehicles, their drivers and contents. The company operates under two reportable segments: Telematics Systems, which provide a series of telematics and stolen vehicle recovery products for the connected vehicle and emerging Internet of Machines marketplace; and Software and Subscription Services, which provide cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open Application Programming Interfaces.

Delta Air Lines provides scheduled air transportation for passengers and cargo. The company serves the Transatlantic, Transpacific and Latin America markets directly on the company and through joint ventures with airline partners. Internationally, the company has hubs and market presence in Amsterdam, London-Heathrow, Mexico City, Paris-Charles de Gaulle and Seoul-Incheon. These arrangements are commercial joint ventures that include joint sales and marketing coordination, co-location of airport facilities and other commercial cooperation arrangements. The company has other businesses arising from its airline operations, including providing maintenance and engineering support for its regional aircraft.

Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in immunology, inflammation and oncology. The company has four clinical-stage product candidates: GB001 (Prostaglandin D2 receptor 2 Antagonist), which is for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions; GB002 (Platelet-derived growth factor Receptor Kinase Inhibitor), which is for the treatment of pulmonary arterial hypertension; GB004 (Hypoxia inducible factor-1a Stabilizer), which is for the treatment of inflammatory bowel disease; and GB1275 (CD11b Modulator), which is for the treatment of oncology indications.

SeaSpine Holdings is a medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients with spinal disorders. The company's products include: orthobiologics, which include particulate and fibers-based demineralized bone matrices, collagen ceramic matrices, demineralized cancellous allograft bone and synthetic bone void fillers; and spinal implants, which consist of a line of products for spinal decompression, alignment, and stabilization. The company's development pipeline consists of modular minimally invasive surgery, additional applications for its NanoMetalene technology, and extensions of its orthobiologics product offerings.

TRACON Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of targeted therapeutics for cancer and wet age-related macular degeneration. The company is developing its primary product candidate, TRC105 (carotuximab), an endoglin antibody, for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor pathway, or in combination with inhibitors of the programmed cell death protein 1 pathway. The company's second clinical stage product oncology candidate is TRC102, a small molecule being developed for the treatment of lung cancer and mesothelioma.